Which is better, palbociclib or abeciclib?

Palbociclib (Palbociclib) and Abemaciclib are both drugs used to treat breast cancer. They are CDK 4/6 inhibitors. They have similar mechanisms of action and efficacy in the treatment of breast cancer. Both palbociclib and abeciclib have demonstrated significant efficacy in clinical trials. However, differences may occur based on the patient's genotype and specific condition.

Pabociclib is suitable for the first-line treatment of hormone receptor-positive (HR+/HER-2-negative) advanced breast cancer and can be used in combination with letrozole or fulvestrant; abeciclib can be used together with endocrine therapy (tamoxifen) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-positive, and high risk of recurrence early-stage breast cancer. Both palbociclib and abeciclib may cause some adverse reactions, such as low blood cell counts, nausea, and hair loss. However, specific adverse effects and tolerability may vary between drugs.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.